Cargando…
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198821/ https://www.ncbi.nlm.nih.gov/pubmed/36847863 http://dx.doi.org/10.1007/s00262-023-03405-7 |
| _version_ | 1785044812658900992 |
|---|---|
| author | Pons-Tostivint, E. Hulo, P. Guardiolle, V. Bodot, L. Rabeau, A. Porte, M. Hiret, S. Demontrond, P. Curcio, H. Boudoussier, A. Veillon, R. Mayenga, M. Dumenil, C. Chatellier, T. Gourraud, P. A. Mazieres, J. Bennouna, J. |
| author_facet | Pons-Tostivint, E. Hulo, P. Guardiolle, V. Bodot, L. Rabeau, A. Porte, M. Hiret, S. Demontrond, P. Curcio, H. Boudoussier, A. Veillon, R. Mayenga, M. Dumenil, C. Chatellier, T. Gourraud, P. A. Mazieres, J. Bennouna, J. |
| author_sort | Pons-Tostivint, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10198821 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101988212023-05-21 Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% Pons-Tostivint, E. Hulo, P. Guardiolle, V. Bodot, L. Rabeau, A. Porte, M. Hiret, S. Demontrond, P. Curcio, H. Boudoussier, A. Veillon, R. Mayenga, M. Dumenil, C. Chatellier, T. Gourraud, P. A. Mazieres, J. Bennouna, J. Cancer Immunol Immunother Correction Springer Berlin Heidelberg 2023-02-27 2023 /pmc/articles/PMC10198821/ /pubmed/36847863 http://dx.doi.org/10.1007/s00262-023-03405-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Pons-Tostivint, E. Hulo, P. Guardiolle, V. Bodot, L. Rabeau, A. Porte, M. Hiret, S. Demontrond, P. Curcio, H. Boudoussier, A. Veillon, R. Mayenga, M. Dumenil, C. Chatellier, T. Gourraud, P. A. Mazieres, J. Bennouna, J. Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title | Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title_full | Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title_fullStr | Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title_full_unstemmed | Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title_short | Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% |
| title_sort | correction to: real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer pd-l1 ≥ 50% |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198821/ https://www.ncbi.nlm.nih.gov/pubmed/36847863 http://dx.doi.org/10.1007/s00262-023-03405-7 |
| work_keys_str_mv | AT ponstostivinte correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT hulop correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT guardiollev correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT bodotl correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT rabeaua correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT portem correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT hirets correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT demontrondp correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT curcioh correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT boudoussiera correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT veillonr correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT mayengam correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT dumenilc correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT chatelliert correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT gourraudpa correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT mazieresj correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 AT bennounaj correctiontorealworldmulticentrecohortoffirstlinepembrolizumabaloneorincombinationwithplatinumbasedchemotherapyinnonsmallcelllungcancerpdl150 |